Company · Healthtech & Bio

Eversens

eversens.com ↗ ·Pamplona ·Seed

Eversens is a Spanish medtech company that designs, develops, manufactures, and commercializes non-invasive breath-analysis devices for detecting exhaled biomarkers, used to diagnose and monitor respiratory diseases like asthma. Its flagship product, evernoa BASE, measures fractional exhaled nitric oxide (FeNO), a biomarker for airway inflammation. Founded in 2015 as a spin-off of the Public University of Navarra (UPNA), it is ISO 13485:2018 certified and based in Pamplona.

Founded

2015

Founders

News

Rounds

Investors

SectorsMedtech, Diagnostics, Respiratory health, Biosensors Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Profile updated 4 Aug 2026

Founders

Francisco J. Arregui

Co-Founder

Ignacio R. Matías

Co-Founder

Juan Mari Pérez Azpeitia

Co-Founder & CTO

Leyre Ruete Ibarrola

CEO & Founding Partner

Global models

No comparables on record yet.

Investors 4

Centro para el Desarrollo Tecnológico y la Innovación

Sodena (Sociedad de Desarrollo de Navarra)

sodena.com

Investor Spain

Start Up Capital Navarra

www.startup.es ↗

Investor Spain

Funding rounds 2

Other

Eversens, developer of the evernoa exhaled-biomarker analysers for airway inflammation, received an undisclosed investment structured as a c…

2024-01-26

Seed · €356K

Eversens is a spin-off of the Public University of Navarra (UPNA) that makes a portable exhaled nitric-oxide meter (Evernoa BASE) for diagno…

2020-07-01

News & media 4

Published	Article
2026-07-23	Navarra investiga el sentido del olfato para anticipar el diagnóstico de enfermedades como el Alzheimer ↗ Noticias de Navarra
2025-02-26	The BREATHE Project: Artificial Intelligence for a Future Without Respiratory Exacerbations ↗ 4YFN (Mobile World Capital)
2024-10-10	Eversens obtiene 356.000 euros en una ronda de financiación ↗ Navarra Capital
2023-10-18	Leyre Ruete Ibarrola Presents everSens at LSI Europe '23 ↗ Life Science Intelligence